Pasireotide comment watch save
BreastfeedingPediatric

  • FDA APPROVAL DATE: 12/14/2012
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Antiarrhythmics, Bromocriptine, Cyclosporine, Drugs prolonging the QT interval

Please login to view the rest of this drug profile.

Page last updated 10/02/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top